Browse the evidence

Tirzepatide treatment in adults with obesity but without pre-existing type 2 diabetes significantly reduces the incidence of new-onset type 2 diabetes compared to semaglutide.

If you have obesity and are at risk for type 2 diabetes, tirzepatide may be a more effective option than semaglutide for preventing the onset of the disease. This is based on real-world data showing a 27% lower risk of developing type 2 diabetes with tirzepatide compared to semaglutide over a one-year follow-up period. Consult your doctor to see if this treatment is appropriate for you.

Tirzepatide treatment in adults with pre-existing type 2 diabetes significantly reduces the risk of major adverse cardiovascular events (MACE), including all-cause mortality and cerebral infarction, compared to semaglutide.

If you have type 2 diabetes, tirzepatide may offer greater cardiovascular protection than semaglutide, including a lower risk of heart attack, stroke, and death. This is based on real-world data showing a 46% lower risk of major adverse cardiovascular events with tirzepatide compared to semaglutide over a one-year follow-up period. Consult your doctor to see if this treatment is appropriate for you.

The association between high carbohydrate intake and increased CVD risk is significantly stronger in Asian populations (1.52-fold increase) compared to non-Asian populations (no significant association), with risk escalating dramatically when carbohydrate intake exceeds 60% of total energy.

If you are of Asian descent, be particularly mindful of your carbohydrate intake. The risk of heart disease increases significantly if carbohydrates make up more than 60% of your calories. Consider reducing your intake of refined carbohydrates and rice to lower this risk.

Phentermine/topiramate combination therapy results in significant weight loss but is associated with increased heart rate and potential psychiatric side effects.

Phentermine/topiramate is a combination pill that can lead to significant weight loss. However, it can increase your heart rate and cause psychiatric side effects like anxiety or depression. It requires careful monitoring by a doctor, and if you don't lose enough weight after a few months, the treatment may be stopped.

Bariatric surgery, particularly Roux-en-Y gastric bypass and biliopancreatic diversion, induces Type 2 Diabetes remission in a majority of patients through mechanisms exceeding simple caloric restriction, including hormonal changes (GLP-1, PYY) and altered gut microbiome.

For eligible patients with obesity and T2DM, bariatric surgery is the most potent intervention for achieving remission, often outperforming medication. It works by altering gut hormones that improve insulin sensitivity, not just by making the stomach smaller. Consultation with a bariatric specialist is required to assess eligibility based on BMI and diabetes duration.

Dual-agonists (GLP-1R/GIPR) and tri-agonists (GLP-1R/GIPR/GCGR) provide superior weight loss and cardiometabolic risk factor improvement (blood pressure, lipids) compared to GLP-1RAs alone, though their direct impact on hard cardiovascular outcomes (MACE) is still under investigation.

Newer medications like Tirzepatide (a dual agonist) may offer greater weight loss and improvements in blood pressure and cholesterol than older GLP-1 drugs. However, long-term data on whether this translates to fewer heart attacks or strokes is still being collected. If standard GLP-1s are not achieving your metabolic goals, discuss these newer options with your doctor.

GLP-1 receptor agonists improve hepatic steatosis and MASH resolution primarily through weight loss and direct inhibition of hepatic de novo lipogenesis.

GLP-1 agonists like semaglutide and liraglutide are effective treatments for MASH, achieving resolution in a significant portion of patients. They work by reducing liver fat through both weight loss and direct metabolic effects. Expect potential gastrointestinal side effects, which are usually manageable.

In real-world clinical practice, semaglutide produces attenuated weight loss (average 4.44%) compared to clinical trials, with diabetes mellitus diagnosis significantly reducing efficacy while linaclotide use and prediabetes are associated with enhanced weight loss.

If you are taking semaglutide in a standard clinical setting, expect an average weight loss of around 4-5% over a year, which is less than the 10-15% often cited from clinical trials. This difference is largely due to the lack of intensive lifestyle counseling provided in routine care. If you have diabetes, your weight loss may be further reduced, whereas having prediabetes or taking linaclotide might actually help you lose more weight.

Concomitant use of linaclotide is associated with significantly greater weight loss in patients taking semaglutide, whereas diabetes mellitus and dulaglutide use are associated with reduced efficacy.

If you are taking semaglutide, your other medications matter. Taking linaclotide (for constipation/IBS) is associated with better weight loss results, while taking diabetes medications like dulaglutide or metformin, or having a diabetes diagnosis, is associated with less weight loss. This suggests that your specific health profile and other drugs significantly influence semaglutide's effectiveness.

Oral semaglutide at 50 mg once daily achieves significantly greater HbA1c reduction (2.1%) and weight loss (9.8%) compared to the approved 14 mg dose, with higher discontinuation rates due to gastrointestinal adverse events.

If you have Type 2 Diabetes and struggle with blood sugar or weight, oral semaglutide 50mg is a potent non-injectable option. It works better than the standard 14mg dose, lowering HbA1c by 2.1% and causing nearly 10% weight loss. However, be prepared for potential stomach issues like nausea, which are common but usually mild. Take it on an empty stomach with a small sip of water as directed.

Short-term time-restricted eating (8-hour window) improves 24-hour glucose homeostasis (reduced area under the curve) compared to an extended 12-hour eating window, despite identical food intake.

Compressing your eating window to 8 hours (e.g., 10 AM to 6 PM) can significantly improve your daily blood glucose control, even if you eat the exact same amount of food as you would over 12 hours. This is achieved by shifting meal times to delay breakfast and finish dinner earlier, which helps manage glucose spikes.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces significant, dose-dependent weight loss (8.5–8.8%) in adults with obesity at doses of 24–36 mg/day, with gastrointestinal side effects being the primary limiting factor.

Take orforglipron once daily. Start at a low dose (6-9 mg) and increase to 12 mg, then to 24-36 mg as tolerated. Expect 8-9% body weight loss over 6 months. Manage nausea by titrating slowly.

Dual agonists of GLP-1 and glucagon (GCGR) or GIP receptors provide greater weight loss and broader metabolic benefits than mono-agonists, potentially addressing treatment barriers like cost and access by treating non-cardiometabolic complications.

If you have obesity, especially with related conditions like diabetes or fatty liver, newer dual-agonist medications (like tirzepatide) may offer significantly greater weight loss and health benefits than older drugs. However, access is currently limited by cost and insurance coverage. Discuss these options with your doctor, focusing on how treating multiple complications might justify the expense.

Unimolecular dual-agonists targeting GLP-1 and GIP receptors (e.g., tirzepatide) provide superior glycemic control and weight loss compared to GLP-1 receptor agonists alone by leveraging additive insulinotropic effects and distinct metabolic pathways.

If you have Type 2 Diabetes and struggle with weight, dual-agonist medications (like tirzepatide) may offer better blood sugar control and weight loss than older GLP-1 drugs. These medications work by mimicking gut hormones to boost insulin, reduce appetite, and increase energy expenditure. While they are injections and may cause temporary nausea, the clinical benefits for metabolic health are significant. Consult your doctor to see if this advanced therapy is appropriate for your specific health profile.

GLP-1 receptor agonists (GLP-1RAs) effectively manage type 2 diabetes and obesity by mimicking endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, and promote satiety through delayed gastric emptying and hypothalamic signaling.

GLP-1 receptor agonists are a proven treatment for Type 2 Diabetes and obesity. They work by mimicking a natural hormone to help your pancreas release insulin when needed, stop the release of sugar-storing hormones, and make you feel full faster. This leads to better blood sugar control and weight loss. While they are effective, they require injections, which can be a barrier for some patients.

GLP-1 receptor agonists induce significant fat mass loss with a non-significant or significantly smaller reduction in muscle mass, resulting in muscle mass accounting for less than 20% of total weight loss.

If you are taking a GLP-1 medication like Ozempic or Wegovy, your body is prioritizing fat loss over muscle loss. While you may lose a small amount of muscle, it is a minor fraction of your total weight loss (under 20%). Focus on maintaining strength through resistance training to preserve the muscle you have, but do not let fear of muscle loss stop you from using effective weight management tools.

GLP-1 receptor agonists (GLP-1RAs) and dual/triple incretin agonists produce clinically relevant hepatic improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH), including MASH resolution, liver fat reduction, and prevention of fibrosis worsening.

If you have MASH or MASLD, especially with obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or tirzepatide) are a valuable treatment option. They not only help with weight and blood sugar but also directly improve liver health by reducing fat and inflammation. While lifestyle changes remain important, these medications can help achieve the necessary weight loss (7-10%) if you struggle to do so alone. Discuss these options with your gastroenterologist.

Among GLP-1 receptor agonists, tirzepatide induces the greatest reduction in body mass index (BMI), while orforglipron demonstrates the strongest benefit in lowering systolic blood pressure.

Not all GLP-1 drugs are equal for every health goal. If your primary concern is significant weight loss, tirzepatide shows the greatest BMI reduction in this analysis. If high blood pressure is the main issue, orforglipron showed the strongest blood pressure-lowering effect. Consult your doctor to choose the agent that best targets your specific cardiometabolic risks.

GLP-1 receptor agonist therapies significantly reduce C-reactive protein (CRP) levels, with semaglutide showing the most efficacious reduction compared to other agents.

GLP-1 therapies also help reduce systemic inflammation, as measured by C-reactive protein (CRP). Semaglutide was found to be particularly effective at lowering CRP levels, which may contribute to its cardiovascular benefits.

GLP-1 receptor agonists (specifically liraglutide) significantly reduce body weight and improve cardiometabolic risk factors (BMI, fasting plasma glucose, lipid profile) in obese or overweight individuals with psychotic disorders treated with antipsychotic drugs.

For patients with psychotic disorders on antipsychotics who struggle with obesity, GLP-1 receptor agonists (especially liraglutide) are a proven, effective treatment for weight loss and improving metabolic health. They significantly reduce body weight, BMI, and improve blood sugar and lipid levels without increasing the risk of stopping treatment compared to standard care. Liraglutide appears more effective than exenatide for weight loss in this group.

GLP-1 receptor agonists significantly improve lipid profiles (reducing Total Cholesterol and LDL-C, increasing HDL-C) and fasting plasma glucose in obese individuals with psychotic disorders, but do not significantly affect waist circumference, systolic/diastolic blood pressure, or triglycerides.

GLP-1 receptor agonists improve blood sugar and cholesterol levels (lowering bad cholesterol and triglycerides, raising good cholesterol) in patients with psychotic disorders, but they do not significantly lower blood pressure or waist circumference. This makes them valuable for metabolic health, even if blood pressure remains unchanged.

Meeting multiple glycemic criteria (IFG, IGT, and/or elevated HbA1c) for prediabetes significantly increases the risk of progressing to type 2 diabetes compared to meeting only one criterion.

If you have prediabetes, ask your doctor to check all three glycemic markers (fasting glucose, 2-hour post-meal glucose, and HbA1c). Meeting more than one abnormal result means your risk of developing type 2 diabetes is much higher, and you should prioritize intensive lifestyle changes or discuss medication with your provider immediately.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to GLP-1 receptor agonists (semaglutide, dulaglutide) and insulin analogs (degludec, glargine) in patients with type 2 diabetes.

If you have Type 2 Diabetes or obesity, Tirzepatide is a once-weekly injection that lowers blood sugar and reduces body weight more effectively than current GLP-1 drugs (like semaglutide) or insulin. It works by mimicking two gut hormones (GIP and GLP-1). Common side effects are gastrointestinal, but they often decrease over time. Consult a doctor to see if you are a candidate.

Current GLP-1-based anti-obesity medications (AOMs) achieve profound acute body weight loss (up to 25%) but are associated with significant real-world treatment discontinuation (up to 50%) due to gastrointestinal side effects and lack of lifestyle counseling, necessitating novel formulations with improved tolerability.

While GLP-1 drugs like semaglutide and tirzepatide produce significant weight loss, real-world adherence is a major hurdle due to gastrointestinal side effects. To maximize success, patients should utilize flexible, patient-determined titration schedules rather than fixed rapid escalation, and consider prophylactic anti-emetics if needed, as these strategies improve long-term tolerability and adherence.